Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice

The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghetti, Alberto, Giacomelli, Andrea, Borghi, Vanni, Ciccullo, Arturo, Dusina, Alex, Fabbiani, Massimiliano, Rusconi, Stefano, Zazzi, Maurizio, Mussini, Cristina, Di Giambenedetto, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314943/
https://www.ncbi.nlm.nih.gov/pubmed/34327247
http://dx.doi.org/10.1093/ofid/ofab103
Descripción
Sumario:The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

Ejemplares similares